+41.1%
MS vs MRNA
+455.8%
-414.7%
-18.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.2% | +0.7% | -2.0% | -1.3% |
| 7D | -2.1% | -8.2% | +6.2% | -2.0% |
| 30D | -1.1% | +125.6% | -126.7% | -2.4% |
| 3M | +3.5% | +197.1% | -193.6% | -1.3% |
| 6M | +33.7% | +148.5% | -114.8% | +29.4% |
| YTD | +21.8% | +363.3% | -341.5% | +10.8% |
| 1Y | +41.1% | +462.0% | -420.9% | +26.8% |
| All | +41.1% | +455.8% | -414.7% | +26.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling